DA32 Life Science Tech Acquisition, a blank check company formed by Deerfield Management, ARCH Venture Partners, and Section 32, raised $200 million by offering 20 million shares at $10. The company did not offer units with warrants attached.
Co-sponsored by Deerfield Management, ARCH Venture Partners, and Section 32, DA32 Life Science Tech Acquisition is led by CEO and Director Steve Kafka, a Managing Partner of Section 32. The company plans to leverage management's background and experience to target the life sciences sector.
DA32 Life Science Tech Acquisition plans to list on the Nasdaq under the symbol DALS. J.P. Morgan, and Cowen acted as joint bookrunners on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
